Among KTRs with treated T2D, there was an overall increase in SGLT2i utilization (both any use and incident use), accompanied by a decline in other GLMs, such as insulin, metformin, and SU over the study period. The gene discussed is INS; the disease is type 2 diabetes mellitus.